Biotech vet Troy Wilson shines a spotlight on his oligonucleotide startup as Eli Lilly signs up for a premier Big Pharma partnership
Troy Wilson is best known now for his role leading Kura Oncology, where the team has been developing targeted cancer drugs. Not so well known is Avidity Biosciences, which he and Kent Hawryluk founded in La Jolla about 6 years ago, using an antibody conjugated with oligonucleotides and siRNA payloads to hit specific targets of their own.
But today they’d like to shed some of that low profile with a premier discovery partnership with Eli Lilly that will bring a much brighter spotlight to the work they’re doing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.